First-In-Human Study of Bispecific Antibody MR001 In Subjects With Advanced Solid Tumors

NCT06134531 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

31

Enrollment

OTHER

Sponsor class

Conditions

Advanced Solid Tumors

Interventions

DRUG: MR001

Sponsor

Nanfang Hospital, Southern Medical University